Monoclonal IgG4/2κ Deposition Following Eculizumab Therapy for Recurrent Atypical Hemolytic Uremic Syndrome in Kidney Transplantation

Kidney Medicine - United States
doi 10.1016/j.xkme.2019.03.005
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Eculizumab in Atypical Hemolytic–Uremic Syndrome

New England Journal of Medicine
Medicine
2013English

Eculizumab Use for Kidney Transplantation in Patients With a Diagnosis of Atypical Hemolytic Uremic Syndrome

Kidney International Reports
Nephrology
2019English

Transplantation in Atypical Hemolytic Uremic Syndrome

Seminars in Thrombosis and Hemostasis
Cardiovascular MedicineHematologyCardiology
2010English

Resolution of Ocular Involvement With Systemic Eculizumab Therapy in Atypical Hemolytic-Uremic Syndrome

Eye
MedicineArtsSensory SystemsOphthalmologyHumanities
2013English

Prophylactic Eculizumab Use in Kidney Transplantation: A Review of the Literature and Report of a Case With Atypical Hemolytic Uremic Syndrome

Annals of Transplantation
MedicineTransplantation
2015English

Atypical Hemolytic-Uremic Syndrome

2020English

Skin Involvement in Atypical Hemolytic Uremic Syndrome

American Journal of Kidney Diseases
Nephrology
2014English

The Genetics of Atypical Hemolytic Uremic Syndrome

Medizinische Genetik
Genetics
2018English

Atypical Hemolytic Uremic Syndrome in the Postpartum Period

Proceedings in Obstetrics and Gynecology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy